<DOC>
	<DOCNO>NCT01075880</DOCNO>
	<brief_summary>The study plan evaluate cognitive function subject RRMS treat interferon beta-1a , relationship fatigue neurological dysfunction status .</brief_summary>
	<brief_title>Post-Authorization Observational Study Evaluate Cognition Fatigue Relapsing-remitting Multiple Sclerosis ( RRMS ) Patients Treated With Rebif®</brief_title>
	<detailed_description>Besides motor sensory dysfunction , progression cognitive decline frequent manifestation RRMS . Fatigue another important symptom MS , negatively affect subject 's Quality life ( QoL ) socio-economic functioning , include ability work , independent direct effect disability . This phase IV observational , non-interventional , prospective , multicentric study evaluate cognition RRMS subject treat Rebif relationship fatigue neurological dysfunction status . The study plan enroll 300 subject , across 14 centre Czech Republic , prescribe Rebif accord summary product characteristic ( SmPC ) . Assessment cognitive fatigue status do baseline follow-up visit Months 3 , 6 , 12 , 24 . Subjects select use convenience method follow non-probability sampling . OBJECTIVES Primary Objective : - To assess change cognition [ measure Paced Auditory Serial Addition Test ( PASAT ) ] RRMS subject treat Rebif Secondary Objectives : - To assess change fatigue [ measure Fatigue Descriptive Scale ( FDS ) ] RRMS subject treat Rebif - To assess correlation cognition , fatigue neurological status RRMS subject treat Rebif - To assess relationship Rebif dosage [ 22 mcg v 44 mcg thrice week ( tiw ) ] cognition ( PASAT ) - To assess relationship Rebif dosage ( 22 mcg v 44 mcg tiw ) fatigue ( FDS ) - To assess adherence Rebif treatment - To explore use antidepressive antifatigue medicament</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Subjects diagnose RRMS Subjects eligible treatment Rebif per SmPC , Czech local guideline actual Health insurance policy . Subjects 1865 year age Subjects EDSS score &lt; 4 Subjects willing able give inform consent Treatment Rebif 24 month prior inform consent form obtain . Subjects history hypersensitivity natural recombinant interferonβ , excipients Female subject pregnant breast feed and/or planning become pregnant Subjects current severe depression and/or suicidal ideation Any contraindication Rebif therapy per SmPC Subjects severe disability and/or neurologic psychiatric condition may interfere test performance Prior treatment interferon beta1a i.m . interferon beta1b glatiramer acetate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Multiple Sclerosis , Relapsing-Remitting</keyword>
	<keyword>Rebif</keyword>
	<keyword>Interferon beta-1a</keyword>
</DOC>